Fecal Microbiota Transplantation in Patients With Ulcerative Colitis
Single Fecal Microbiota Transplantation Via Colonoscope as an Adjunct Therapy in the Treatment of Ulcerative Colitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Turku, Finland, 20520
- Turku University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- active ulcerative colitis (PUCAI 10-64) in whom fecal microbiota transplantation via colonoscope can be performed
Exclusion Criteria:
- severe ulcerative colitis (PUCAI > 65)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Fecal microbiota transplantation
A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
|
A single fecal microbiota transplantation through colonoscope
|
|
No Intervention: Standard medical treatment
Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Activity of ulcerative colitis
Time Frame: Within 1 year after the intervention
|
Change from baseline in the Pediatric Ulcerative Colitis Activity Index (PUCAI) at 1 month, 3 months, 6 months, and 12 months.
|
Within 1 year after the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Colonic inflammation
Time Frame: Within 1 year after the intervention
|
Change from baseline in the fecal calprotectin at 1 month, 3 months, 6 months, and 12 months.
|
Within 1 year after the intervention
|
|
Colonic inflammation
Time Frame: Within 1 year after the intervention
|
Endoscopic Mayo score at 3 and 12 months after the intervention
|
Within 1 year after the intervention
|
|
Adverse events
Time Frame: Within 1 year after the intervention
|
Within 1 year after the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marko Kalliomäki, MD, Turku University Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15881
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.